<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Calcium <z:chebi fb="68" ids="48706">antagonists</z:chebi> are currently under investigation as potential beneficial drugs in the prevention of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, some calcium <z:chebi fb="68" ids="48706">antagonists</z:chebi> have the propensity to inhibit platelet aggregation </plain></SENT>
<SENT sid="2" pm="."><plain>This study investigated the danger posed by the administration of calcium <z:chebi fb="68" ids="48706">antagonists</z:chebi> for recurrent <z:mp ids='MP_0001914'>hemorrhage</z:mp> in a simulated rat model of <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We found that <z:chebi fb="1" ids="9948">verapamil</z:chebi>, a calcium <z:chebi fb="68" ids="48706">antagonist</z:chebi> with antiplatelet activity, lowers clot resistance and may promote rebleeding </plain></SENT>
</text></document>